Generated by AI
Pulse Biosciences Inc is a bioelectric medicine company focused on developing and commercializing medical technologies that use proprietary pulsed-field energy to treat targeted cells while preserving surrounding tissue. Its current product portfolio includes the nPulse System for benign skin lesions, the nPulse Vybrance Percutaneous Electrode system for soft tissue ablation, the nPulse Cardiac Surgical Clamp for atrial fibrillation procedures, the nPulse Cardiac Catheter System for circumferential cardiac ablation, and the nPulse Console, a software-enabled platform designed to support physician workflows. The company serves healthcare providers across dermatology, surgical soft-tissue care, and cardiac electrophysiology, with applications centered on minimally invasive treatment approaches. Pulse Biosciences Inc positions itself within the medical device market through its proprietary energy-based platform, which is designed for clinical use in areas where precise cellular targeting is important.
Website601 Brickell Key Drive
Miami, FL, 33131
United States
The latest articles about PLSE.
Pulse Biosciences Inc (PLSE) wrapped up enrollment in its NanoPulse AF pivotal IDE study three months early while reporting a wider GAAP net loss of $23.1 million and roughly two years of cash runway.
Summary of Sep 9's posts. Generated by AI.
Summary of Feb 6's posts. Generated by AI.
Summary of Feb 9's posts. Generated by AI.
Investors talking about PLSE also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.